STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma
The signal transducer and activator of transcription 3 (STAT3) is a transcription factor that,
when dysregulated, becomes a powerful oncogene found in many human cancers …
when dysregulated, becomes a powerful oncogene found in many human cancers …
A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines
RE Culpin, SJ Proctor, B Angus… - International …, 2010 - spandidos-publications.com
The microRNAs are endogenous, non-coding RNAs that play key roles in a range of
pathophysiological processes by up-or down-regulating gene expression. Recent studies …
pathophysiological processes by up-or down-regulating gene expression. Recent studies …
[HTML][HTML] Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B …
K Linton, C Howarth, M Wappett, G Newton… - The Journal of molecular …, 2012 - Elsevier
Refractory/relapsed diffuse large B-cell lymphoma (DLBCL) has a poor prognosis. Novel
drugs targeting the constitutively activated NF-κB pathway characteristic of ABC-DLBCL are …
drugs targeting the constitutively activated NF-κB pathway characteristic of ABC-DLBCL are …
Evaluation of immunohistochemical subtypes in diffuse large B-cell lymphoma and its impact on survival
A Dwivedi, A Mehta, P Solanki - Indian Journal of Pathology and …, 2015 - journals.lww.com
Materials and Methods: A total of 83 patients of DLBCL were included in the study.
Hematoxylin-and eosin-stained sections were prepared from the paraffin-embedded tissue …
Hematoxylin-and eosin-stained sections were prepared from the paraffin-embedded tissue …
[HTML][HTML] QuantiGene Plex represents a promising diagnostic tool for cell-of-origin subtyping of diffuse large B-cell lymphoma
JS Hall, S Usher, RJ Byers, RC Higgins… - The Journal of Molecular …, 2015 - Elsevier
Emerging therapies targeting the molecularly distinct GCB and non-GCB/ABC subtypes of
diffuse large B-cell lymphoma (DLBCL) have created the need to develop an accurate …
diffuse large B-cell lymphoma (DLBCL) have created the need to develop an accurate …
Discriminant analysis and machine learning approach for evaluating and improving the performance of immunohistochemical algorithms for COO classification of …
Y Perfecto-Avalos, A Garcia-Gonzalez… - Journal of translational …, 2019 - Springer
Background Diffuse large B-cell lymphoma (DLBCL) is classified into germinal center-like
(GCB) and non-germinal center-like (non-GCB) cell-of-origin groups, entities driven by …
(GCB) and non-germinal center-like (non-GCB) cell-of-origin groups, entities driven by …
[HTML][HTML] Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era
Gene expression profiling studies have distinguished diffuse large B-cell lymphomas
(DLBCLs) by cell of origin, with distinct pathogenetic mechanisms and prognosis. We …
(DLBCLs) by cell of origin, with distinct pathogenetic mechanisms and prognosis. We …
Morphological, immunophenotypic and molecular characterization of mature aggressive B-cell lymphomas in Chinese pediatric patients
B Lu, C Zhou, W Yang, H Huang, Z Gao… - Leukemia & …, 2011 - Taylor & Francis
Differential diagnosis of Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and
B cell lymphoma, unclassifiable, with features intermediate between BL and DLBCL …
B cell lymphoma, unclassifiable, with features intermediate between BL and DLBCL …
[HTML][HTML] Clinicopathological study of gene rearrangement and microRNA expression of primary central nervous system diffuse large B-cell lymphomas
J Zheng, J Xu, S Ma, X Sun, M Geng… - International journal of …, 2013 - ncbi.nlm.nih.gov
We studied the clinicopathological and imaging characteristics of primary central nervous
system diffuse large B-cell lymphomas (PCNS-DLBCL). Imaging, pathologic histology, and …
system diffuse large B-cell lymphomas (PCNS-DLBCL). Imaging, pathologic histology, and …
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and …
C Panizo, AJ Rodríguez, G Gutiérrez, FJ Díaz… - … Myeloma and Leukemia, 2015 - Elsevier
Introduction Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity, showing a
highly variable outcome. In patients with DLBCL relapsed/refractory to first-line treatment …
highly variable outcome. In patients with DLBCL relapsed/refractory to first-line treatment …